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believe that our conclusion suggesting that Lp(a) by itself is not a risk
factor for ischemic heart disease (1) is erroneous. Although some
prospective population-based studies have found Lp(a) to be an
independent risk factor for ischemic heart disease (2,3), we must bear
in mind that the bulk of the data supporting that conclusion is derived
from case-control studies. The studies of Hopkins et al. (4) and
Orth-Gome´r et al. (5), which are mentioned by Drs. Enas and Metha,
fall into that category. In the former, 160 young subjects with docu-
mented ischemic heart disease were matched to 165 control subjects. A
subgroup of 27 patients and five control subjects with elevated Lp(a)
and total cholesterol had a relative risk of 13.8 of developing ischemic
heart disease (4). Although this may look extremely impressive when
compared with our risk of 2.96 (1), I do not think that the two studies
can be compared. Our study is prospective, population based with at
least 215 subjects in each subgroup of analysis. These numbers alone
can account for the differences. The latter study, also case-control, is a
study of women younger than 65 years (5). Risk factors for this group
are different than those for the men in our study. The inherent
selection biases associated with case-control studies will favor the
inclusion of subjects with altered lipid profiles as well as other ischemic
heart disease risk factors. Therefore, these data should be interpreted
with caution.
The PROCAM study is also a population-based prospective co-
hort; in the report of Assmann et al. (6) there is a significant risk of
ischemic heart disease associated with elevated Lp(a). However, it
must not be forgotten that in that particular report, only 863 of the
4381 participants included had Lp(a) measurements. I do not want to
underestimate the importance Lp(a) may have in ischemic heart
disease; it is clearly a risk factor when associated with other risk
factors. However, I still think that there is a lack of prospective
population based studies supporting a role for Lp(a) as an independent
risk factor. Considering this, I do not think that Lp(a) measurements
should be carried out in a primary prevention setting.
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Functional Assessment of Coronary Stenoses
I read the article by Bech et al. regarding deferral of angioplasty on
intermediate coronary stenoses based on measured coronary flow
reserve with interest (1). The authors addressed an important issue,
that of interventional revascularization procedures being performed
on obstructive lesions of “intermediate” severity by angiography
without objective evidence of ischemia and therefore uncertain influ-
ence on outcome.
I take issue, however, with the statement in the conclusion of their
article, that deferral of PTCA based on FFRmyo is safe “irrespective of
the noninvasive stress test result.” If the authors are considering stress
ECG testing, their statement may be correct as it is known that
abnormalities on treadmill tolerance tests do not correlate well with
functional severity of coronary lesions. Stress nuclear perfusion scin-
tigraphy, with either thallium or technetium based agents, however, is
reflective of the functional significance of an underlying stenosis. Dr.
N. Pijls (one of the authors of the present study), nicely demonstrated
in an earlier paper the strong relationship between an FFRmyo ,0.75
and ischemia demonstrated either by stress thallium scintigraphy or
dobutamine echocardiography (2). This study, in fact, used the nonin-
vasive test results as the reference standard as three patients of 211
with FFR $0.75 were said to have “false negative results” as their
stress tests were positive.
It is also widely appreciated that provocative testing with nuclear or
echocardiographic imaging have quite good positive predictive values
regarding future coronary events. An original study by K. Brown
showed in a series of 100 patients that compared with clinical, stress
ECG, and angiographic data, the best predictor of future events was
the number of segments with reversible thallium defects (3).
Therefore, if the authors use of the term “noninvasive stress test”
includes the above-described imaging modalities, I would be interested
in seeing more data before abandoning such diagnostic techniques.
Although all noninvasive testing modalities for detecting coronary
artery disease have less than optimal sensitivity and specificity depend-
ing on the patient population, I don’t feel the evidence is there to
support the use of intracoronary pressure recording in favor of “stress
testing”.
GREGORY L. MILLER, MD, FACC
Grand River Cardiology, P.C.
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Reply
We appreciate the comments of Dr. Miller, which give us the oppor-
tunity to clarify the use of coronary pressure and fractional flow
reserve in case of intermediate stenosis.
Generally, we believe that a decision to perform myocardial
revascularization should be based upon objective proof of inducible
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myocardial ischemia. Ideally, such proof should be obtained before the
patient is on the table for PTCA or surgery. Therefore, the first tools
to confirm reversible myocardial ischemia as the cause of chest pain
are noninvasive tests, of which exercise nuclear perfusion scintigraphy
is probably most widely used. This implicates that in a patient with
typical chest pain, a significant coronary artery stenosis, and a positive
nuclear test, it is not necessary at all to do invasive physiologic
assessment of that coronary lesion. In such cases, revascularization can
be performed straightforward.
However, in contrast to official guidelines, in many countries
(among which the USA) PTCA is performed in many patients without
documented proof of reversible schemia (1). In those cases, noninva-
sive tests were negative, not conclusive, or just not performed. In such
cases, in our opinion, it is mandatory to measure fractional flow reserve
to justify subsequent PTCA.
The clinical problem sketched above is especially pronounced in
case of intermediate stenosis or in patients with atypical chest pain. It
is well known that in such patients, if they persist to complain, coronary
angiography is often performed despite negative (nuclear) stress
testing and that merely the visible presence of a stenosis in those cases
triggers coronary intervention (oculo-stenotic reflex). Such a problem
was present in the majority of the patient population described in our
recent paper (2).
In the remaining 28 patients, a positive regular exercise test was
present. In those cases coronary pressure measurements were per-
formed because of the discrepancy between the positive exercise test
and either the chest pain or the moderate severity of the coronary
artery stenosis. We have argued that in such a population the incidence
of false-positive exercise testing is rather high, and the favorable
outcome of our patients after deferral of a PTCA supports that
position. If in all these patients nuclear scintigraphy had been per-
formed, probably many of these tests would have been (true) negative
because of the higher specificity of nuclear exercise testing compared
with exercise testing alone. It should be kept in mind, however, that
especially in the case of intermediate stenosis, the accuracy of nuclear
stress testing is not as high as desirable, as shown in our recent paper
in the New England Journal of Medicine (3). In that paper it was shown
that the diagnostic accuracy of invasive FFR determination was as high
as the combined accuracy of exercise testing, nuclear scintigraphy, and
stress-echo and higher than that of any noninvasive single test if
performed alone.
In conclusion, we acknowledge the great value of nuclear stress
testing for noninvasive assessment of coronary artery disease and
emphasize that—with very few exceptions—objective evidence of
reversible ischemia should be documented in any way before perform-
ing a revascularization procedure.
However, if that has not been done, as is often the case, or if the
results of noninvasive tests are not conclusive or contrasting to other
clinical data, justification of performing a PTCA on one hand or
deferring the PTCA on the other hand can be found by measuring
coronary pressure and fractional flow reserve just prior to the planned
intervention.
NICO H. J. PIJLS, MD, PhD
Department of Cardiology
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Familial Dilated Cardiomyopathy
Gru¨nig et al. (1) have reported the results of their detailed examina-
tion of a large number of relatives of probands with dilated cardiomy-
opathy (DCM) and have concluded that up to 35% of patients with
DCM may have an inherited disorder. Their work makes a valuable
contribution to the area of inherited cardiac disease and emphasises
the need for careful history taking and assessment of relatives in cases
where the disease may, otherwise, appear to be sporadic in nature.
However, there are several points that need to be addressed.
First, they report a family history and pedigree analysis negative for
familial DCM in 289 of the 445 index patients. However, in this group,
only 231 family members were examined—this means that in at least
58 cases familial disease cannot be definitely excluded and it would
have been more appropriate to classify these as indeterminate rather
than negative. Second, the definition of “suspected” DCM is rather
loose and thereby creates the potential for mis-classification of familial
disease. Third, the classification of the familial cases into six groups
based on characteristic features and prognosis is helpful in defining
patterns of disease. However, the authors do not attempt to address
the issue of autosomal recessive disease (2).
Fourth, the description of the phenotype (from A to F) changes
between Table 2 and Tables 3/4. Fifth, the inference from Table 2 is
that all cases of phenotype A are caused by mutations in the dystrophin
gene but, on perusal of the text, this has been validated for only one
family.
Finally, there are numerous instances where the numbers quoted in
the table do not agree with the text and careful examination of the
pedigrees also reveals some discrepancies.
1. Figure 1: the number of cases classified as “suspected familial
DCM” should read n 5 108 (not n 5 110).
2. Table 1: in the section under “functional status” the numbers
under “course,” “transplantation,” and “death” do
not add up correctly—are the groups mutually exclu-
sive? The data set under “X-ray findings” is incom-
plete but no explanation is offered in the text.
3. Page 188: the numbers in the text “On examination, concomi-
tant cardiac abnormalities, such as unspecific ECG
changes. . . . ” do not add up to 120.
4. Table 3: the numbers in the section “functional status at
diagnosis” do not add up correctly—no explanation is
given in the text to account for missing data.
5. Figure 2: according to my interpretation of the pedigree IV-12
is the cousin and not the nephew of the index case
IV-16. Three females are classified as affected but the
text on page 189 reports depressed LV function in
only two cases. This also leads on to difficulty with the
numbers reported in Table 3 under Phenotype A.
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